Heterogeneous outcomes in metabolic dysfunction-associated steatotic liver disease/steatohepatitis with type 2 diabetes: Rethinking risk and management approaches.

Gosnell and colleagues executed a large-scale cohort investigation delineating ethnic disparities in outcomes among individuals with metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH). Uncovering such heterogeneity is pivotal to optimising management and prognostication, notably for hepatocellular carcinoma, fibrotic progression, and all-cause mortality. The authors furnish granular trajectories for Hispanic non-Hispanic populations across the United States and southeastern Texas, alongside a comprehensive appraisal of MASLD/MASH-related event rates. These insights provide an indispensable framework for early risk stratification and the tailoring of therapeutic algorithms and surveillance regimens. The study underscores the necessity for nuanced appreciation of MASLD/MASH outcome profiles and associated management strategies, while interrogating regional variation in disease burden, the benefits of integrated metabolic care, and the potential of lifestyle interventions to attenuate complications and improve prognosis.